Methods and compositions for prevention and treatment of Apicomplexan infections

Patent metadata

Field	Value
Publication number	US-11135231-B2
Application number	US-201716467320-A
Country	US
Kind code	B2
Filing date	Dec 7, 2017
Priority date	Dec 7, 2016
Publication date	Oct 5, 2021
Grant date	Oct 5, 2021

Abstract

Methods and compositions for preventing and/or treating diseases and conditions caused by certain apicomplexan infections are provided. The methods involve administering/providing to a subject one or more of tartrolon D and E, including isomers thereof. Exemplary apicomplexan infections that are prevented/treated by the compounds of the invention include those caused by Cryptosporidium, Babesia, Cyclospora, Isospora, Plasmodium, Sarcocystis, Besnoitia, Hammondia, Neospora, Theileria and Toxoplasma.

First claim

What is claimed is:

1. A method of treating or preventing a disease caused by an apicomplexan parasite in a subject in need thereof, comprising administering to the subject at least one of tartrolon D and E, in an amount that is therapeutically effective against the apicomplexan parasite.

2. The method of claim 1 , wherein the at least one of tartrolon D and E has been purified.

3. The method of claim 1 , wherein the apicomplexan parasite is a Cryptosporidium species.

4. The method of claim 1 , wherein the apicomplexan parasite is Toxoplasma gondii.

5. The method of claim 1 , wherein the apicomplexan parasite is a Babesia species.

6. The method of claim 5 , wherein the apicomplexan parasite is Babesia bovis.

7. The method of claim 1 , wherein the apicomplexan parasite is a Plasmodium species.

8. The method of claim 7 , wherein the apicomplexan parasite is Plasmodium falciparum or Plasmodium malariae.

9. The method of claim 1 , wherein the apicomplexan parasite is selected from the group consisting of Cyclospora, Isospora, Eimeria, Sarcocystis, Theileria, Besnoitia, Hammondia , and Neospora.

10. The method of claim 1 , wherein the disease is cryptosporidiosis.

11. The method of claim 1 , wherein the disease is toxoplasmosis.

12. The method of claim 1 , wherein the disease is babesiosis.

13. The method of claim 1 , wherein the disease is malaria.

14. The method of claim 1 , wherein the disease is selected from the group consisting of cyclosporiasis, isosporiasis, sarcocystosis, besnoitiosis, hammondiosis, neosporiasis and theileriosis.

15. The method of claim 1 , further comprising administering to the subject tartrolon D or E or both in a dose of at least about 2 mg for every kg of the subject's weight.

16. The method of claim 1 , further comprising administering to the subject a second anti-parasitic agent against the same parasite.

17. The method of claim 1 , further comprising administering to the subject both tartrolon D and E.

18. The method of claim 1 , wherein the subject is selected from the group consisting of human, horse, sheep, goat, bovine, chicken, turkey, duck, goose, dog, cat, pig, rabbit, donkey, camels, llamas, alpaca, kangaroo, wallaby, lemur, birds, penguin, sea lion, seal, and sea otter.

Assignees

• Tufts Medical Ct Inc
• Univ Washington State
• Univ Utah Res Found
• Univ Utah

Inventors

• O'Connor Roberta
• Schmidt Eric W

Classifications

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/69 Primary

  Boron compounds · CPC title

• A61K31/365

  Lactones · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61P33/06

  Antimalarials · CPC title